Quantification of tumour and circulating vascular endothelial growth factor (VEGF) in patients with oesophagogastric cancer: A long-term follow-up study

British Journal of Biomedical Science

Volumn 69, Issue 2, 2012, Pages 71-75

  Gray, Ronan T ^a   O'Donnell, M E ^a,b   McGuigan, J A ^c   Spence, G M ^a  

^a ULSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Esophagus; Neoplasms; Stomach; Vascular endothelial growth factors

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TISSUE LEVEL;

EID: 84865196729     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2012.12002440     Document Type: Article

References (21)

1. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997; 79: 1-8.
2. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18 (1): 4-25. (Pubitemid 27076453)
3. Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004; 87 (2): 95-104. (Pubitemid 39079657)
4. Ku GY, Ilson DH. Esophagogastric cancer: targeted agents. Cancer Treat Rev 2010; 36 (3): 235-48.
5. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19 (4): 1207-25. (Pubitemid 32176299)
6. Hyodo I, Doi T, Endo H et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998; 34 (13): 2041-5. (Pubitemid 28546939)
7. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pretreatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998; 79 (2): 144-6. (Pubitemid 28201685)
8. Spence GM, Graham AN, Mulholland K et al. Vascular endothelial growth factor levels in serum and plasma following esophageal cancer resection-relationship to platelet count. Int J Biol Markers 2002; 17 (2): 119-24. (Pubitemid 34873797)
9. Spence GM, Graham AN, Mulholland K et al. Bone marrow micrometastases and markers of angiogenesis in esophageal cancer. Ann Thorac Surg 2004; 78 (6): 1944-9. (Pubitemid 39556265)
10. Hermanek P, Hutter RV, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86 (12): 2668-73. (Pubitemid 30004671)
11. Sobin LH, Wittekind eds. UICC TNM Classification of Malignant Tumours 5th edn. New York: John Wiley & Sons, 1997.
12. Crew JP, O'Brien T, Bradburn M et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57 (23): 5281-5. (Pubitemid 27516364)
13. Adams J, Carder PJ, Downey S et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000; 60 (11): 2898-905. (Pubitemid 30395813)
14. Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 1998; 18 (2B): 1251-4. (Pubitemid 28234025)
15. Banks RE, Forbes MA, Kinsey SE et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77 (6): 956-64. (Pubitemid 28101786)
16. Wynendaele W, Derua R, Hoylaerts MF et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol 1999; 10 (8): 965-71. (Pubitemid 29424578)
17. Ogata Y, Fujita H, Yamana H, Sueyoshi S, Shirouzu K. Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study. World J Surg 2003; 27 (5): 584-9. (Pubitemid 36961131)
18. Tanaka T, Ishiguro H, Kuwabara Y et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res 2010; 29: 83.
19. Mobius C, Freire J, Becker I et al. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 2007; 31 (9): 1768-72. (Pubitemid 47283174)
20. Kozlowski M, Kowalczuk O, Milewski R, Chyczewski L, Niklinski J, Laudanski J. Serum vascular endothelial growth factors C and D in patients with oesophageal cancer. Eur J Cardiothorac Surg 2010; 38 (3): 260-7.
21. Kimura H, Kato H, Tanaka N et al. Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer. Anticancer Res 2008; 28 (1A): 165-9.